Public Employees Retirement System of Ohio lessened its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 32.8% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 174,421 shares of the company’s stock after selling 85,007 shares during the quarter. Public Employees Retirement System of Ohio owned approximately 0.07% of Cellebrite DI worth $2,791,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of CLBT. Assetmark Inc. bought a new stake in shares of Cellebrite DI during the first quarter worth $33,000. Catalyst Capital Advisors LLC bought a new stake in shares of Cellebrite DI during the first quarter worth $51,000. Virtus Advisers LLC bought a new stake in shares of Cellebrite DI during the first quarter worth $63,000. Advisors Asset Management Inc. grew its stake in shares of Cellebrite DI by 24.7% in the first quarter. Advisors Asset Management Inc. now owns 6,133 shares of the company’s stock worth $119,000 after purchasing an additional 1,214 shares during the last quarter. Finally, JT Stratford LLC bought a new stake in shares of Cellebrite DI in the first quarter worth $209,000. Institutional investors own 45.88% of the company’s stock.
Analysts Set New Price Targets
CLBT has been the topic of several analyst reports. Needham & Company LLC reduced their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, August 14th. Lake Street Capital reduced their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, August 15th. Wall Street Zen raised shares of Cellebrite DI from a “hold” rating to a “buy” rating in a research note on Friday, September 26th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 24th. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $21.75.
Cellebrite DI Trading Down 0.2%
Shares of CLBT opened at $18.50 on Thursday. The stock has a market capitalization of $4.43 billion, a P/E ratio of -24.34, a price-to-earnings-growth ratio of 3.37 and a beta of 1.29. The firm’s fifty day simple moving average is $16.07 and its two-hundred day simple moving average is $16.98. Cellebrite DI Ltd. has a 12 month low of $13.10 and a 12 month high of $26.30.
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. The business had revenue of $113.28 million for the quarter, compared to analysts’ expectations of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 earnings per share. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.
About Cellebrite DI
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles
- Five stocks we like better than Cellebrite DI
- 3 Monster Growth Stocks to Buy Now
- Datavault AI: The New AI Contender Backed by Big Funding
- What does consumer price index measure?
- CoreWeave: Why the New King of AI Infrastructure Has Room to Run
- Retail Stocks Investing, Explained
- Top 3 Dividend Achievers for October: High Yields, Growth Ahead
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.